In silico metabolism studies of dietary flavonoids by CYP1A2 and CYP2C9

Food Research International

Volumn 50, Issue 1, 2013, Pages 102-110

  Sousa, Mariana C ^a   Braga, Rodolpho C ^a   Cintra, Bertilha A S ^a   de Oliveira, Valéria ^a   Andrade, Carolina H ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

CYP; Cytochrome P450; Dietary flavonoids; Docking; Metabolism; SOM

Indexed keywords

ACTIVE SITE; AMINO ACID RESIDUES; CANCER PREVENTION; CHRONIC DISORDERS; CYP; CYTOCHROME P450; IN-SILICO; ISOFORMS; NARINGIN; SOM; SUGAR CHAIN;

AMINO ACIDS; DOCKING; FATTY ACIDS; METABOLISM; PHENOLS; PHYSIOLOGY;

FLAVONOIDS;

EID: 84868238030     PISSN: 09639969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.foodres.2012.09.027     Document Type: Article

References (52)

1. Adams, S. E. (2010). Molecular Similarity and Xenobiotic Metabolism. Ph.D. Thesis, Cambridge, U.K.: University of Cambridge.
2. Andres A., Donovan S.M., Kuhlenschmidt M.S. Soy isoflavones and virus infections. The Journal of Nutritional Biochemistry 2009, 20(8):563-569.
3. Androutsopoulos V.P., Mahale S., Arroo R.R.J., Potter G. Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncology Reports 2009, 21(6):1525-1528.
4. Androutsopoulos V.P., Papakyriakou A., Vourloumis D., Tsatsakis A.M., Spandidos D.A. Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacology & Therapeutics 2010, 126(1):9-20.
5. Androutsopoulos V.P., Papakyriakou A., Vourloumis D., Spandidos D.A. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorganic & Medicinal Chemistry 2011, 19(9):2842-2849.
6. Arroo R.R.J., Androutsopoulos V., Beresford K., Ruparelia K., Surichan S., Wilsher N., et al. Phytoestrogens as natural prodrugs in cancer prevention: Dietary flavonoids. Phytochemistry Reviews 2009, 8(2):375-386.
7. Bowers K.J., Sacerdoti F.D., Salmon J.K., Shan Y., Shaw D.E., Chow E., et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM/IEEE Conference on Supercomputing (SC06) 2006, 84.
8. Boyer S., Arnby C.H., Carlsson L., Smith J., Stein V., Glen R.C. Reaction site mapping of xenobiotic biotransformations. Journal of Chemical Information and Modeling 2007, 47(2):583-590.
9. Braga R.C., Alves V.M., Fraga C.A.M., Barreiro E.J., de Oliveira V., Andrade C.H. Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. Journal of Molecular Modeling 2012, 18(5):2065-2078.
10. Breinholt V.M., Offord E.A., Brouwer C., Nielsen S.E., Brøsen K., Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food and Chemical Toxicology 2002, 40(5):609-616.
11. Breinholt V.M., Rasmussen S.E., Brøsen K., Friedberg T.H. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. Pharmacology & Toxicology 2003, 93(1):14-22.
12. Carlsson L., Spjuth O., Adams S., Glen R.C., Boyer S. Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse. BMC Bioinformatics 2010, 11(1):362.
13. Czodrowski P., Kriegl J.M., Scheuerer S., Fox T. Computational approaches to predict drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 2009, 5(1):15-27.
14. da Silva E.L., Piskula M.K., Yamamoto N., Moon J.H., Terao J., Silva E.L. Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma. FEBS Letters 1998, 430(3):405-408.
15. Dai R., Zhai S., Wei X., Pincus M.R., Vestal R.E., Friedman F.K. Inhibition of human cytochrome P450 1A2 by flavones: A molecular modeling study. Journal of Protein Chemistry 1998, 17(7):643-650.
16. de Groot M.J., Ekins S. Pharmacophore modeling of cytochromes P450. Advanced Drug Delivery Reviews 2002, 54(3):367-383.
17. de Montellano P.R.O. Cytochrome P450: Structure, mechanism, and biochemistry 2010, 664.
18. Doostdar H., Burke M.D., Mayer R.T. Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2001, 144(2000):31-38.
19. Ekins S., de Groot M.J., Jones J.P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metabolism and Disposition 2001, 29(7):936-944.
20. Hadjokas N.E., Dai R., Friedman F.K., Spence M.J., Cusack B.J., Vestal R.E., et al. Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells. British Journal of Pharmacology 2002, 136(3):347-352.
21. Heim K.E., Tagliaferro A.R., Bobilya D.J. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. The Journal of Nutritional Biochemistry 2002, 13(10):572-584.
22. Hodek P., Trefil P., Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chemico-Biological Interactions 2002, 139(1):1-21.
23. Hosny M., Dhar K., Rosazza J.P.N. Hydroxylations and methylations of quercetin, fisetin, and catechin by streptomyces g riseus. Journal of Natural Products 2001, 64(4):462-465.
24. Huey R., Morris G.M., Olson A.J., Goodsell D.S. A semiempirical free energy force field with charge-based desolvation. Journal of Computational Chemistry 2007, 28(6):1145-1152.
25. Iori F., da Fonseca R., Ramos M.J., Menziani M.C. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorganic & Medicinal Chemistry 2005, 13(14):4366-4374.
26. Jorgensen W.L., Maxwell D.S., Tirado-Rives J. Development and testing of the OPLS All-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society 1996, 118(45):11225-11236.
27. Kagawa H., Takahashi T., Ohta S., Harigaya Y. Oxidation and rearrangements of flavanones by mammalian cytochrome P450. Xenobiotica 2004, 34(9):797-810.
28. Kirchmair J., Williamson M.J., Tyzack J.D., Tan L., Bond P.J., Bender A., et al. Computational prediction of metabolism: Sites, products, SAR, P450 enzyme dynamics, and mechanisms. Journal of Chemical Information and Modeling 2012, 52(3):617-648.
29. Kroemer R.T. Structure-based drug design: Docking and scoring. Current Protein & Peptide Science 2007, 8(4):312-328.
30. Lampila P., van Lieshout M., Gremmen B., Lähteenmäki L. Consumer attitudes towards enhanced flavonoid content in fruit. Food Research International 2009, 42(1):122-129.
31. Lewis D.F.V., Lake B.G., Dickins M. Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: molecular modelling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1. Xenobiotica 2004, 34(6):501-513.
32. Liu J., Ericksen S.S., Sivaneri M., Besspiata D., Fisher C.W., Szklarz G.D. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Archives of Biochemistry and Biophysics 2004, 424(1):33-43.
33. Miners J.O., Birkett D.J. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998, 45(6):525-538.
34. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009, 30(16):2785-2791.
35. Nebert D.W., Dieter M.Z. The evolution of drug metabolism. Pharmacology 2000, 61(3):124-135.
36. Nielsen S.E., Breinholt V., Justesen U., Cornett C., Dragsted L.O. In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica 1998, 28(4):389-401.
37. Oda A., Yamaotsu N., Hirono S. New AMBER force field parameters of heme iron for cytochrome P450s determined by quantum chemical calculations of simplified models. Journal of Computational Chemistry 2005, 26(8):818-826.
38. Rathee P., Chaudhary H., Rathee S., Rathee D., Kumar V., Kohli K. Mechanism of action of flavonoids as anti-inflammatory agents: A review. Inflammation & Allergy Drug Targets 2009, 8(3):229-235.
39. Rice-Evans C. Flavonoid antioxidants. Current Medicinal Chemistry 2001, 8(7):797-807.
40. Rydberg P., Vasanthanathan P., Oostenbrink C., Olsen L. Fast prediction of cytochrome P450 mediated drug metabolism. ChemMedChem 2009, 4(12):2070-2079.
41. Sansen S., Yano J.K., Reynald R.L., Schoch G.A., Griffin K.J., Stout C.D., et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. The Journal of Biological Chemistry 2007, 282(19):14348-14355.
42. Scalbert A., Williamson G. Dietary intake and bioavailability of polyphenols. Journal of Nutrition 2000, 130(8):2073S-2085S.
43. Smith D.A., Jones B.C., Walker D.K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Medicinal Research Reviews 1996, 16(3):243-266.
44. Smith D.A., Ackland M.J., Jones B.C. Properties of cytochrome P450 isoenzymes and their substrates Part 1: Active site characteristics. Drug Discovery Today 1997, 2(10):406-414.
45. Smith D.A., Ackland M.J., Jones B.C. Properties of cytochrome P450 isoenzymes and their substrates part 2: Properties of cytochrome P450 substrates. Drug Discovery Today 1997, 2(11):479-486.
46. Stjernschantz E., Vermeulen N.P.E.N.P.E., Oostenbrink C. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. Expert Opinion on Drug Metabolism & Toxicology 2008, 4(5):513-527.
47. Sun H., Scott D.O. Structure-based drug metabolism predictions for drug design. Chemical Biology & Drug Design 2010, 75(1):3-17.
48. Sykes M.J., McKinnon R.A., Miners J.O. Prediction of metabolism by cytochrome P450 2C9: Alignment and docking studies of a validated database of substrates. Journal of Medicinal Chemistry 2008, 51(4):780-791.
49. Tarcsay Á., Keseru G.M. In silico site of metabolism prediction of cytochrome P450-mediated biotransformations. Expert Opinion on Drug Metabolism & Toxicology 2011, 7(3):299-312.
50. Vauzour D., Vafeiadou K., Rodriguez-Mateos A., Rendeiro C., Spencer J.P.E. The neuroprotective potential of flavonoids: A multiplicity of effects. Genes & Nutrition 2008, 3(3-4):115-126.
51. Wang R., Lai L., Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. Journal of Computer-Aided Molecular Design 2002, 16:11-26.
52. Wester M.R., Yano J.K., Schoch G.a., Yang C., Griffin K.J., Stout C.D., et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. The Journal of Biological Chemistry 2004, 279(34):35630-35637.